Literature DB >> 16912482

Detection of lymphatic invasion in early stage primary colorectal cancer with the monoclonal antibody D2-40.

G Walgenbach-Bruenagel1, R H Tolba, A D Varnai, M Bollmann, A Hirner, K J Walgenbach.   

Abstract

PURPOSE: The purpose of this study was to investigate the presence of lymphatic invasion detected by D2-40 immunostaining compared to conventional hematoxylin-eosin (HE) staining in primary colorectal cancer (CRC) and the development of focal new lymphangiogenesis and peritumoral lymphatic proliferation in relation to the tumor stages. Additionally, we analyzed the relation of peritumoral inflammatory reaction (PIR) to tumor stages in CRC. The identification of new categories of patients with high-risk CRC would be very helpful in improving treatment strategies and patient outcome especially in early CRC. PATIENTS AND
METHOD: Biopsies were taken from 41 patients with colorectal adenocarcinomas at different stages of disease. Immunohistochemistry was performed on paraffin-embedded sections. First, the whole section was screened for the presence of lymphatic invasion and PIR with routine HE staining. After analysis of the HE-stained slides, the slides were destained and reused for immunohistochemistry with the D2-40 monoclonal antibody. D2-40-immunostained sections were screened for the presence of lymphatic invasion, the proliferation of lymphatic vessels and focally newly developed lymph vessels.
RESULTS: Using the D2-40 antibody for immunostaining, our results demonstrate a significantly higher detection (p < 0.05) of lymphatic vessel invasion compared to routine HE staining in primary CRC. 22% more patients with lymphatic vessel invasion could be identified compared to routine HE staining, especially in node-negative tumor stage (UICC II). The positive predictive value of lymphatic invasion evaluated by D2-40 immunostaining to predict lymph node metastasis is 92% (negative predictive value 81%). High PIR was shown in UICC stage I and II. These infiltrations were rarely seen in UICC stage III and were absent in UICC stage IV. Higher UICC tumor stage is associated with a higher rate of focally newly developed lymphatic vessels. In UICC stage I we found peritumoral lymphatic vessel proliferation only in one case (14%) and in UICC stage II no case was found. 47% of the cases in UICC stage III and 50% of the cases in UICC stage IV showed focal peritumoral lymphatic vessel proliferation.
CONCLUSIONS: Immunostaining with D2-40 significantly increased the detection rate of lymphatic invasion compared to conventional HE staining in primary CRC. The D2-40 antibody specific for lymphatic endothelium cells has the potential for a prognostic marker in early stage CRC. Further prospective studies are necessary to evaluate the prognostic value of lymphatic invasion and the induction of tumor lymphangiogenesis and its role in human cancer progression. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912482     DOI: 10.1159/000095086

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  21 in total

1.  Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma.

Authors:  Wenjun Wang; Zhu-lin Yang; Jie-qiong Liu; Song Jiang; Xiong-ying Miao
Journal:  Tumour Biol       Date:  2011-11-12

Review 2.  Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer.

Authors:  Hiroo Wada; Manabu Shiozawa; Kayoko Katayama; Naoyuki Okamoto; Yohei Miyagi; Yasushi Rino; Munetaka Masuda; Makoto Akaike
Journal:  J Gastroenterol       Date:  2015-03-01       Impact factor: 7.527

3.  Lymphatic vessel invasion detected by monoclonal antibody D2-40 as a predictor of lymph node metastasis in T1 colorectal cancer.

Authors:  M Ishii; M Ota; S Saito; Y Kinugasa; S Akamoto; I Ito
Journal:  Int J Colorectal Dis       Date:  2009-04-23       Impact factor: 2.571

4.  Lymphovascular invasion in colorectal cancer: an interobserver variability study.

Authors:  Elizabeth I Harris; David N Lewin; Hanlin L Wang; Gregory Y Lauwers; Amitabh Srivastava; Yu Shyr; Bashar Shakhtour; Frank Revetta; Mary K Washington
Journal:  Am J Surg Pathol       Date:  2008-12       Impact factor: 6.394

5.  Double immunohistochemistry enhances detection of lymphatic and venous invasion in early-stage colorectal cancer.

Authors:  A J Ervine; H A McBride; P J Kelly; M B Loughrey
Journal:  Virchows Arch       Date:  2015-06-16       Impact factor: 4.064

6.  Lymphatic invasion identified with D2-40 immunostaining as a risk factor of nodal metastasis in T1 colorectal cancer.

Authors:  Hiroo Wada; Manabu Shiozawa; Nobuhiro Sugano; Soichiro Morinaga; Yasushi Rino; Munetaka Masuda; Makoto Akaike; Yohei Miyagi
Journal:  Int J Clin Oncol       Date:  2012-11-01       Impact factor: 3.402

7.  Malignant colorectal polyps.

Authors:  Luis Bujanda; Angel Cosme; Ines Gil; Juan I Arenas-Mirave
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

8.  A detailed appraisal of mesocolic lymphangiology--an immunohistochemical and stereological analysis.

Authors:  Kevin Culligan; Rishabh Sehgal; Daniel Mulligan; Colum Dunne; Stewart Walsh; Fabio Quondamatteo; Peter Dockery; J Calvin Coffey
Journal:  J Anat       Date:  2014-07-19       Impact factor: 2.610

9.  Long-Term Outcomes of Endoscopic Versus Surgical Resection of Superficial Submucosal Colorectal Cancer.

Authors:  Ji-Beom Kim; Ho Su Lee; Hyo Jeong Lee; Jihun Kim; Dong-Hoon Yang; Chang Sik Yu; Jin Cheon Kim; Jeong-Sik Byeon
Journal:  Dig Dis Sci       Date:  2015-01-14       Impact factor: 3.199

10.  Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases.

Authors:  Xiao-Lei Wang; Jian-Ping Fang; Ru-Yong Tang; Xi-Mei Chen
Journal:  BMC Cancer       Date:  2010-06-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.